Literature DB >> 28687573

Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit.

Shumei Kato, Vivek Subbiah, Razelle Kurzrock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28687573      PMCID： PMC6317845          DOI： 10.6004/jnccn.2017.0127

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  9 in total

1.  Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

Authors:  Denis L Jardim; Denis L Fontes Jardim; Maria Schwaederle; Caimiao Wei; J Jack Lee; David S Hong; Alexander M Eggermont; Richard L Schilsky; John Mendelsohn; Vladimir Lazar; Razelle Kurzrock
Journal:  J Natl Cancer Inst       Date:  2015-09-15       Impact factor: 13.506

Review 2.  Omics and therapy - a basis for precision medicine.

Authors:  Joseph P Garay; Joe W Gray
Journal:  Mol Oncol       Date:  2012-03-08       Impact factor: 6.603

3.  Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis.

Authors:  Vivek Subbiah; Razelle Kurzrock
Journal:  JAMA Oncol       Date:  2016-06-01       Impact factor: 31.777

Review 4.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.

Authors:  Sandip Pravin Patel; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2015-02-18       Impact factor: 6.261

5.  Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.

Authors:  Jennifer J Wheler; Filip Janku; Aung Naing; Yali Li; Bettzy Stephen; Ralph Zinner; Vivek Subbiah; Siqing Fu; Daniel Karp; Gerald S Falchook; Apostolia M Tsimberidou; Sarina Piha-Paul; Roosevelt Anderson; Danxia Ke; Vincent Miller; Roman Yelensky; J Jack Lee; David S Hong; Razelle Kurzrock
Journal:  Cancer Res       Date:  2016-05-18       Impact factor: 12.701

6.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors:  David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

Review 7.  Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

Authors:  Maria Schwaederle; Melissa Zhao; J Jack Lee; Alexander M Eggermont; Richard L Schilsky; John Mendelsohn; Vladimir Lazar; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

8.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Authors:  Christophe Le Tourneau; Jean-Pierre Delord; Anthony Gonçalves; Céline Gavoille; Coraline Dubot; Nicolas Isambert; Mario Campone; Olivier Trédan; Marie-Ange Massiani; Cécile Mauborgne; Sebastien Armanet; Nicolas Servant; Ivan Bièche; Virginie Bernard; David Gentien; Pascal Jezequel; Valéry Attignon; Sandrine Boyault; Anne Vincent-Salomon; Vincent Servois; Marie-Paule Sablin; Maud Kamal; Xavier Paoletti
Journal:  Lancet Oncol       Date:  2015-09-03       Impact factor: 41.316

9.  Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.

Authors:  Maria Schwaederle; Melissa Zhao; J Jack Lee; Vladimir Lazar; Brian Leyland-Jones; Richard L Schilsky; John Mendelsohn; Razelle Kurzrock
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777
  9 in total
  9 in total

1.  Biomarkers and their impact on precision medicine.

Authors:  William Slikker
Journal:  Exp Biol Med (Maywood)       Date:  2017-09-19

2.  Building a Phase 1 Cancer Research Program: Lessons Learned and Progress Made.

Authors:  Marc R Matrana; Julia Cook
Journal:  Ochsner J       Date:  2017

Review 3.  Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma.

Authors:  R Andrew Harkins; Andres Chang; Sharvil P Patel; Michelle J Lee; Jordan S Goldstein; Selin Merdan; Christopher R Flowers; Jean L Koff
Journal:  Expert Rev Hematol       Date:  2019-09-12       Impact factor: 2.929

4.  Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.

Authors:  Ryosuke Okamura; Amélie Boichard; Shumei Kato; Jason K Sicklick; Lyudmila Bazhenova; Razelle Kurzrock
Journal:  JCO Precis Oncol       Date:  2018-11-15

5.  Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Authors:  Jason K Sicklick; Shumei Kato; Ryosuke Okamura; Maria Schwaederle; Michael E Hahn; Casey B Williams; Pradip De; Amy Krie; David E Piccioni; Vincent A Miller; Jeffrey S Ross; Adam Benson; Jennifer Webster; Philip J Stephens; J Jack Lee; Paul T Fanta; Scott M Lippman; Brian Leyland-Jones; Razelle Kurzrock
Journal:  Nat Med       Date:  2019-04-22       Impact factor: 53.440

6.  Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment.

Authors:  Andrea Botticelli; Pamela Vernocchi; Federico Marini; Andrea Quagliariello; Bruna Cerbelli; Sofia Reddel; Federica Del Chierico; Francesca Di Pietro; Raffaele Giusti; Alberta Tomassini; Ottavia Giampaoli; Alfredo Miccheli; Ilaria Grazia Zizzari; Marianna Nuti; Lorenza Putignani; Paolo Marchetti
Journal:  J Transl Med       Date:  2020-02-03       Impact factor: 5.531

7.  Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial.

Authors:  Jakob M Riedl; Samantha O Hasenleithner; Gudrun Pregartner; Lukas Scheipner; Florian Posch; Karin Groller; Karl Kashofer; Stephan W Jahn; Thomas Bauernhofer; Martin Pichler; Herbert Stöger; Andrea Berghold; Gerald Hoefler; Michael R Speicher; Ellen Heitzer; Armin Gerger
Journal:  Ther Adv Med Oncol       Date:  2021-02-27       Impact factor: 8.168

8.  Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies.

Authors:  Diviya Gupta; Razelle Kurzrock; Suzanna Lee; Ryosuke Okamura; Hyo Jeong Lim; Ki Hwan Kim; Jason K Sicklick; Shumei Kato
Journal:  NPJ Precis Oncol       Date:  2022-03-28

Review 9.  Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas.

Authors:  Jaewan Jeon; Sungmin Lee; Hyunwoo Kim; Hyunkoo Kang; HyeSook Youn; Sunmi Jo; BuHyun Youn; Hae Yu Kim
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.